429 related articles for article (PubMed ID: 23621532)
21. Crown ethers reverse P-glycoprotein-mediated multidrug resistance in cancer cells.
Guberović I; Marjanović M; Mioč M; Ester K; Martin-Kleiner I; Šumanovac Ramljak T; Mlinarić-Majerski K; Kralj M
Sci Rep; 2018 Sep; 8(1):14467. PubMed ID: 30262858
[TBL] [Abstract][Full Text] [Related]
22. A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer.
Tian F; Dahmani FZ; Qiao J; Ni J; Xiong H; Liu T; Zhou J; Yao J
Acta Biomater; 2018 Jul; 75():398-412. PubMed ID: 29874597
[TBL] [Abstract][Full Text] [Related]
23. Strategies to overcome or circumvent P-glycoprotein mediated multidrug resistance.
Yuan H; Li X; Wu J; Li J; Qu X; Xu W; Tang W
Curr Med Chem; 2008; 15(5):470-6. PubMed ID: 18289002
[TBL] [Abstract][Full Text] [Related]
24. Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression.
Nobili S; Landini I; Mazzei T; Mini E
Med Res Rev; 2012 Nov; 32(6):1220-62. PubMed ID: 21374643
[TBL] [Abstract][Full Text] [Related]
25. SERCA and P-glycoprotein inhibition and ATP depletion are necessary for celastrol-induced autophagic cell death and collateral sensitivity in multidrug-resistant tumor cells.
Xu SW; Law BYK; Qu SLQ; Hamdoun S; Chen J; Zhang W; Guo JR; Wu AG; Mok SWF; Zhang DW; Xia C; Sugimoto Y; Efferth T; Liu L; Wong VKW
Pharmacol Res; 2020 Mar; 153():104660. PubMed ID: 31982489
[TBL] [Abstract][Full Text] [Related]
26. Wilforine resensitizes multidrug resistant cancer cells via competitive inhibition of P-glycoprotein.
Chang YT; Lin YC; Sun L; Liao WC; Wang CCN; Chou CY; Morris-Natschke SL; Lee KH; Hung CC
Phytomedicine; 2020 Jun; 71():153239. PubMed ID: 32447245
[TBL] [Abstract][Full Text] [Related]
27. 5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells.
Ranjbar S; Khonkarn R; Moreno A; Baubichon-Cortay H; Miri R; Khoshneviszadeh M; Saso L; Edraki N; Falson P; Firuzi O
Toxicol Appl Pharmacol; 2019 Jan; 362():136-149. PubMed ID: 30391378
[TBL] [Abstract][Full Text] [Related]
28. Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies.
Li W; Zhang H; Assaraf YG; Zhao K; Xu X; Xie J; Yang DH; Chen ZS
Drug Resist Updat; 2016 Jul; 27():14-29. PubMed ID: 27449595
[TBL] [Abstract][Full Text] [Related]
29. Nanotherapeutics approaches to overcome P-glycoprotein-mediated multi-drug resistance in cancer.
Halder J; Pradhan D; Kar B; Ghosh G; Rath G
Nanomedicine; 2022 Feb; 40():102494. PubMed ID: 34775061
[TBL] [Abstract][Full Text] [Related]
30. Nanomedicine to overcome cancer multidrug resistance.
Yang X; Yi C; Luo N; Gong C
Curr Drug Metab; 2014; 15(6):632-49. PubMed ID: 25255871
[TBL] [Abstract][Full Text] [Related]
31. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Bar-Zeev M; Livney YD; Assaraf YG
Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
[TBL] [Abstract][Full Text] [Related]
32. Enhancing Activity of Anticancer Drugs in Multidrug Resistant Tumors by Modulating P-Glycoprotein through Dietary Nutraceuticals.
Khan M; Maryam A; Mehmood T; Zhang Y; Ma T
Asian Pac J Cancer Prev; 2015; 16(16):6831-9. PubMed ID: 26514453
[TBL] [Abstract][Full Text] [Related]
33. A polypeptide based podophyllotoxin conjugate for the treatment of multi drug resistant breast cancer with enhanced efficiency and minimal toxicity.
Zhou H; Lv S; Zhang D; Deng M; Zhang X; Tang Z; Chen X
Acta Biomater; 2018 Jun; 73():388-399. PubMed ID: 29694920
[TBL] [Abstract][Full Text] [Related]
34. Quercetin and doxorubicin co-encapsulated biotin receptor-targeting nanoparticles for minimizing drug resistance in breast cancer.
Lv L; Liu C; Chen C; Yu X; Chen G; Shi Y; Qin F; Ou J; Qiu K; Li G
Oncotarget; 2016 May; 7(22):32184-99. PubMed ID: 27058756
[TBL] [Abstract][Full Text] [Related]
35. Not only P-glycoprotein: Amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins.
Genovese I; Ilari A; Assaraf YG; Fazi F; Colotti G
Drug Resist Updat; 2017 May; 32():23-46. PubMed ID: 29145976
[TBL] [Abstract][Full Text] [Related]
36. Relevance of multidrug resistance in the age of targeted therapy.
Türk D; Szakács G
Curr Opin Drug Discov Devel; 2009 Mar; 12(2):246-52. PubMed ID: 19333870
[TBL] [Abstract][Full Text] [Related]
37. Evading P-glycoprotein mediated-efflux chemoresistance using Solid Lipid Nanoparticles.
Cavaco MC; Pereira C; Kreutzer B; Gouveia LF; Silva-Lima B; Brito AM; Videira M
Eur J Pharm Biopharm; 2017 Jan; 110():76-84. PubMed ID: 27810470
[TBL] [Abstract][Full Text] [Related]
38. Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells.
Nanayakkara AK; Follit CA; Chen G; Williams NS; Vogel PD; Wise JG
Sci Rep; 2018 Jan; 8(1):967. PubMed ID: 29343829
[TBL] [Abstract][Full Text] [Related]
39. Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy.
Beretta GL; Cavalieri F
Curr Med Chem; 2016; 23(1):3-22. PubMed ID: 26438248
[TBL] [Abstract][Full Text] [Related]
40. Modulation of P-glycoprotein by Stemona alkaloids in human multidrug resistance leukemic cells and structural relationships.
Umsumarng S; Pitchakarn P; Yodkeeree S; Punfa W; Mapoung S; Ramli RA; Pyne SG; Limtrakul P
Phytomedicine; 2017 Oct; 34():182-190. PubMed ID: 28899501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
